Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466611 | 0.83 | TDP1 (0.51) | SLC40A1POLBKDM4ELMNAMAPK1 | |
| SCHEMBL6541197 | 0.80 | SLC40A1 (0.62) | SLC40A1POLBLMNAFFAR4KEAP1 | |
| SCHEMBL3714382 | 0.78 | TDP1 (0.50) | SLC40A1POLBKDM4ELMNAMAPK1 | |
| SCHEMBL29086564 | 0.76 | TDP1 (0.51) | SLC40A1POLBKDM4ELMNAMAPK1 | |
| SCHEMBL7272538 | 0.76 | KDM4E (0.66) | POLBKDM4EATMTDP1MAPT | |
| SCHEMBL9117916 | 0.76 | SLC40A1 (0.48) | SLC40A1POLBKDM4ELMNAATM | |
| SCHEMBL8629880 | 0.75 | CA1 (0.57) | SLC40A1POLBKDM4ELMNAATM | |
| Methyl Alcohol SCHEMBL27853401 | 0.75 | TDP1 (0.50) | SLC40A1POLBKDM4ELMNAATM | |
| SCHEMBL1040743 | 0.75 | ALDH1A1 (0.60) | SLC40A1POLBTDP1ALDH1A1MEN1 | |
| SCHEMBL16674253 | 0.74 | TSHR (0.59) | SLC40A1POLBKDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | SLC40A1 1519/4885POLB 4663/4885KDM4E 3629/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | SLC40A1 1231/4885POLB 4842/4885KDM4E 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.